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The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identiﬁes a
distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demon-
strated that EGFR tyrosine kinase inhibitors (TKIs) geﬁtinib and erlotinib are superior to standard
chemotherapy in this subset of tumors. Nevertheless, in many cases, responses are not durable and last
for 6e12 months due to the occurrence of secondary or acquired resistance. Here we present three cases
of EGFR-mutant lung adenocarcinomas (ADC), that showed an unexpected response to anti-EGFR small
molecules. The ﬁrst patient presented a continued 89 month-long response to erlotinib in a tumor
recurred after surgery and conventional chemotherapy. In the other cases, subclinically persistent tumor
in the lung tissue was documented histologically in lung resections performed after partial response to
TKI treatment. The persistence of interstitial and endolymphatic tumor cells after TKI treatment might
explain the common observation of tumor relapse after TKI discontinuation, and sustain the decision to
continue treatment in responsive patients as in our ﬁrst case.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Epidermal growth factor receptor (EGFR)-mutant non-small-cell
lung cancer (NSCLC) identiﬁes a distinct and clinically relevant
molecular subset of lung cancer. Activating EGFR somatic mutations
have emerged as the most relevant predictor of response to small
EGFR tyrosine kinase inhibitors (TKIs) and it is now well demon-
strated that in patients whose tumors harbor EGFRmutations, EGFR
TKIs, geftinib and erlotinib, are superior to chemotherapy in terms
of response rates, progression free survival, quality of life and
toxicity proﬁle. Nevertheless in many cases responses are not du-
rable, as more often TKI stabilize the disease for 6e12 months
followed by the occurrence of secondary or acquired resistance [1].ar Medicine, Laboratory of
rsity and Fondazione IRCCS
).
Ltd. This is an open access article uHere we present three EGFR-mutant lung adenocarcinoma
(ADC) patients, worth to be reported due to their unusual response
to anti-EGFR small molecules. Clinical and molecular details are
reported in Tables 1 and 2. The ﬁrst is a 61-year-old Caucasian,
never smoker female who in 2005 underwent left superior lung
lobectomy for an early stage (T1N0M0 [2]) ADC.Mutational analysis
performed on the resected tumor tissue revealed a deletion
affecting exon 19 of the EGFR gene, without gene ampliﬁcation,
whereas no mutations were found in KRAS exon 2, PIK3CA exons
9e20, BRAF exon 15 coding sequences; neither HER2 ampliﬁcation
nor mutation were documented. Molecular analyses were per-
formed as previously described [3]. Based on disease stage adjuvant
therapy was not administered. Regular clinical and imaging follow
up in 2006 showed at CT scan a mediastinal lymphadenopathy
suggestive for disease progression. Subsequent CT-guided biopsy
conﬁrmed the diagnosis of lymphnode metastasis of lung ADC.
Metastatic cells carried the same genetic proﬁle of the primary
tumor. Subsequent analysis demonstrated the absence of EML4/ALKnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical data on the three patients described.
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scan after three cycles showed disease progression with the
appearance of a small nodule in the left lung and the coexistence of
pathological mediastinal lymphnodes. Based on the mutational
proﬁle of both tumor and secondary lesion, erlotinib 150 mg/day
was started at the beginning of 2007. The ﬁrst CT control after three
months of treatment revealed a slight reduction ofmalignant lesion
size. A further reduction was documented after 6 months of ther-
apy, in September 2007. Quite unexpectedly, the patient is since
then showing a prolonged response with persistent disease control
after 89 months of continued therapy, in absence of signiﬁcant
toxicities (mild anemia). Related CT scan images are reported in
Fig. 1.
A 65-year-old former smoker Caucasian woman was diagnosed
in 2012 with an ADC of left inferior lobe, associated with medias-
tinal lymphoadenopathy and pleural secondary lesions. Based on
the detection of the L858R EGFR mutation, therapy with geﬁtinib
was started. CT scan after six months of therapy showed a partial
response with shrinkage of the tumor primary lesion, complete
resolution of the pleural effusion, and stability of hilar nodes. After
a multidisciplinary evaluation, the patient underwent surgical lo-
bectomy. The histological examination of the surgical sample
showed a ﬁbroelastotic area corresponding to the lesion docu-
mented on CT, associated with diffuse interstitial and lymphatic
spread of minute tumor aggregates in subpleural, perivascular and
peribronchial areas. No evidence of interstitial lung disease was
documented. Treatment with geﬁtinib was thus resumed and
continued until now (months) in absence of clinically detectable
disease recurrence. The last patient was a 49-year-old former
smoker Caucasian, who was diagnosed in 2012 with stage IV lung
ADC, metastatic to the brain (single lesion). The tumor carried a
deletion of the exon 19 of the EGFR coding sequence. Whole brain
radiotherapy (30 Gy) was started in association to geﬁtinib. CT scan
after six months of therapy demonstrated a single lung nodule, in
absence of brain and abdominal disease. After a multidisciplinary
evaluation, lung tumor was resected. On histological examination,
focal ﬁbroelastosis was identiﬁed, and minute tumor aggregates
were observed in the perivascular and peribronchial interstitium
and lymphatics with a micronodular appearance. Interstitial lung
disease was not observed. Based on these data, geﬁtinib was
continued until disease progression 8 months after surgery.Table 2
Molecular proﬁle of the analyzed cases. For case 2 and 3, in green data red data obtained o
evaluated in only surgical specimen to analyze the status of transducers involved in acqNotably, in both case 2 and 3 known molecular mechanisms of
genetic resistance to EGFR inhibitors were tested on bioptic sam-
ples at diagnosis and on subsequent available surgical specimens:
no EGFR T790M mutation were documented and tumors DNA
harbored a wild type KRAS andMET coding sequences, no EGFR and
MET gene ampliﬁcations were found as well. Case 2 and 3 histo-
logical and CT scan images are presented in Fig. 1.
The EGFR TKIs, geﬁtinib and erlotinib, act as reversible
competitive inhibitors of the tyrosine kinase domain of EGFR that
bind to its adenosine-50 triphosphate-binding site. Somatic EGFR
activating mutations in NSCLC have been associated with dramatic
tumor responses and favorable clinical outcomes with these mol-
ecules. However, most patients who initially respond to geﬁtinib
and erlotinib eventually become resistant and experience disease
progression. We present here the case of a really continued
response - nearly a complete disease remission - induced by erlo-
tinib in an advanced EGFR-mutant lung ADC, which recurred after
surgery and the failure of conventional chemotherapy. This is to our
knowledge among the most impressive documented responses to
EGFR TKIs in NSCLC, deserving some considerations. A major point
concerns the therapeutic context in which such a prolonged
treatment must be placed. It is known that maintenance therapy
with erlotinib or geﬁtinib produces a signiﬁcant increase of
progression-free survival (PFS) and overall survival (OS) in NSCLC
patients [4]. Nevertheless, it is conceivable that the persistently
responsive phenotype observed here might be driven by a tumor
and/or host genetic asset which cooperates in sustaining addiction
[5] to the small TKI. In order to verify this hypothesis we checked
the molecular proﬁle of a panel of genes involved in the EGFR
signaling pathway, which are known to play a major role in lung
malignant transformation, and no mutation was documented.
Altered expression of the ERCC1 gene was not identiﬁed as well
(data not shown). Another relevant issue is related to if and when
TKI should be discontinued in responsive patients, mainly when,
after prolonged treatment, imaging data continue to be negative for
disease evidence. In other words, in such unexpected setting (as in
the ﬁrst case reported) is it allowed to stop anti EGFR therapy? In
order to answer to this question, we present two other cases which
are not relevant for the duration of response to small EGFR in-
hibitors, but really because for both of them large surgical speci-
mens of tumors exposed to TKIs are available for histo-patologicaln biopsy at diagnosis and conﬁrmed on subsequent surgical specimens; in blue data
uired resistance to anti EGFR agents.
Fig. 1. Patient 1 CT scans obtained at the time of ﬁrst diagnosis, at tumor recurrence after surgery, after the ﬁrst 6 months of TKI therapy, documenting a reduction of the lesion size,
and at 89 months follow-up, showing persistent response to TKI. Patient 2 and 3 CT scan at diagnosis and after TKI treatment, showing almost complete response; electron mi-
crographs of the resected lung specimen, with interstitial inﬁltration and microembolic diffusion of tumor cells (arrow), in the absence of an obvious tumor mass, in both cases
(hematoxylin and eosin, 20x); follow-up CT scan, showing tumor recurrence in patient 2, 13 months after diagnosis, and absence of disease in patient 3, 19 months after diagnosis.
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sights on how TKIs behave at the microscopic level. Indeed, while it
is well documented that genetic variation in EGFR pathway genes
may confer susceptibility to interstitial lung diseases (ILDs) [6,7]
very few morphological data are available on the tumor histologi-
cal response to small EGFR inhibitors. We observed in both cases
the disappearance of the initial tumor mass, however associated
with the diffuse persistence of tumor cell aggregates in the
lymphatic vessel. This observation has so far not been reported in
the few studies analyzing post-TKI lung resections [8e10], most of
which focused on early tumor response to neoadjuvant treatment.
The subclinical persistence of interstitial and endolymphatic tumor
cells after prolonged TKI treatment might explain the common
observation of tumor relapse after TKI discontinuation, and sustain
the decision to continue treatment in responsive patients as we did
in our ﬁrst case. Clearly, further investigations are required to
deﬁne the molecular proﬁle of these persistently responsive pa-
tients and to distinguish them from the vast majority of those that
develop acquired resistance.
Written informed consent was obtained from the patient for
publication of this Case report and any accompanying images. A
copy of the written consent is available for review by the Editor-in-
Chief of this journal.References
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